- Home
- MYGN vs XYF Comparison
MYGN vs XYF Comparison
Compare MYGN & XYF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- XYF
- Stock Information
- Founded
- MYGN 1991
- XYF 2014
- Country
- MYGN United States
- XYF China
- Employees
- MYGN N/A
- XYF N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- XYF Finance: Consumer Services
- Sector
- MYGN Health Care
- XYF Finance
- Exchange
- MYGN Nasdaq
- XYF Nasdaq
- Market Cap
- MYGN 625.5M
- XYF 708.7M
- IPO Year
- MYGN 1995
- XYF 2018
- Fundamental
- Price
- MYGN $6.65
- XYF $11.65
- Analyst Decision
- MYGN Hold
- XYF
- Analyst Count
- MYGN 14
- XYF 0
- Target Price
- MYGN $13.23
- XYF N/A
- AVG Volume (30 Days)
- MYGN 1.1M
- XYF 169.6K
- Earning Date
- MYGN 11-03-2025
- XYF 11-21-2025
- Dividend Yield
- MYGN N/A
- XYF 4.82%
- EPS Growth
- MYGN N/A
- XYF 41.77
- EPS
- MYGN N/A
- XYF 5.32
- Revenue
- MYGN $825,300,000.00
- XYF $1,047,188,328.00
- Revenue This Year
- MYGN $0.06
- XYF N/A
- Revenue Next Year
- MYGN $5.68
- XYF N/A
- P/E Ratio
- MYGN N/A
- XYF $2.18
- Revenue Growth
- MYGN 0.21
- XYF 45.10
- 52 Week Low
- MYGN $3.76
- XYF $6.04
- 52 Week High
- MYGN $16.83
- XYF $20.36
- Technical
- Relative Strength Index (RSI)
- MYGN 41.25
- XYF 35.48
- Support Level
- MYGN $6.25
- XYF $11.42
- Resistance Level
- MYGN $6.83
- XYF $12.57
- Average True Range (ATR)
- MYGN 0.43
- XYF 0.44
- MACD
- MYGN -0.09
- XYF -0.02
- Stochastic Oscillator
- MYGN 23.90
- XYF 13.99
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About XYF X Financial each representing six
X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, and guarantee services provided.